What is the most likely diagnosis given a progressive rise in prostate-specific antigen from 11.6 ng/mL to 12.3 ng/mL to 15.7 ng/mL over time, with consistently low‑normal serum sodium (≤136 mmol/L)?

Progressive Prostate Cancer with Biochemical Recurrence

The most likely diagnosis is progressive or recurrent prostate cancer, indicated by the steadily rising PSA values from 11.6 to 15.7 ng/mL over time. The consistently low-normal sodium (≤136 mmol/L) is likely incidental or related to other factors, as it does not have a direct established relationship with prostate cancer diagnosis.

Interpretation of Rising PSA

The pattern you describe—PSA values of 11.6 → 12.3 → 15.7 ng/mL—demonstrates biochemical progression. While the provided guidelines focus primarily on post-treatment PSA recurrence definitions 1, the absolute PSA values above 10 ng/mL combined with progressive elevation strongly suggest:

• Active prostate cancer (if treatment-naïve)
• Biochemical recurrence (if post-treatment)
• Disease progression (if on androgen deprivation therapy)

Key Diagnostic Considerations:

PSA velocity matters significantly. The PSA doubling time and velocity are critical prognostic factors 2. Your patient's PSA increased by approximately 35% over the observation period, which warrants urgent evaluation. Research shows that baseline PSA >10 ng/mL and rapid PSA velocity independently predict shorter time to bone metastasis and worse overall survival 3.

Treatment history is essential. The interpretation differs dramatically based on:

• No prior treatment: PSA >10 ng/mL suggests intermediate-to-high risk disease requiring staging and definitive therapy
• Post-radical prostatectomy: Any detectable PSA ≥0.2 ng/mL (confirmed on repeat) constitutes biochemical recurrence 1
• Post-radiation therapy: The ASTRO definition (3 consecutive PSA rises above nadir) or Phoenix criteria (nadir + 2 ng/mL) define recurrence 1
• On androgen deprivation: Rising PSA indicates castration-resistant disease 3

The Sodium Finding

The consistently low-normal sodium (≤136 mmol/L) is not diagnostically specific for prostate cancer. However, consider:

• SIADH from metastatic disease: Advanced prostate cancer with extensive bone or visceral metastases can rarely cause syndrome of inappropriate antidiuretic hormone secretion
• Medication effects: If on androgen deprivation therapy or other medications
• Unrelated causes: Volume status, diuretics, other comorbidities

This sodium level does not change the primary diagnosis but may indicate more advanced disease if truly related.

Critical Next Steps

Immediate workup required:

1. Confirm treatment history: Determine if this is untreated disease, post-definitive therapy, or progression on treatment
2. Repeat PSA: Confirm the rising trend with measurement at ≥4-week intervals 2
3. Calculate PSA kinetics: Determine PSA doubling time and velocity, as these independently predict outcomes 2, 3
4. Staging imaging: Given PSA >10 ng/mL, obtain bone scan and cross-sectional imaging to assess for metastatic disease
5. Testosterone level: If on androgen deprivation, confirm castrate levels (<50 ng/dL)

Important Caveats

Atypical presentations exist but are rare. While most prostate cancers produce PSA proportional to disease burden, be aware that:

• Small cell or neuroendocrine variants may progress with minimal PSA elevation 4
• Non-prostatic PSA-producing tumors (e.g., salivary gland adenocarcinoma) can mimic prostate cancer 5
• However, these represent <1% of cases and should not delay standard evaluation

The rising PSA pattern you describe is classic for progressive prostate cancer and demands immediate urologic evaluation and staging.